To analyze the safety of biologic (DMARDs-b) and synthetic targeted therapies (DMARDs-sd) in the BIOBADAGUAY registry (Paraguayan-Uruguayan registry of adverse events (AEs) in patients with inflammatory rheumatic diseases).
Methods
BIOBADAGUAY is a registry to prospectively evaluate the efficacy and safety of FAME-b and FAME-sd. The full methodology is available at https://biobadaguay.ser.es. Variables associated with the safety of the therapies were used for the present study. The incidence of AA was calculated as incidence rate (IR) per 1000 patient-years, with 95% confidence intervals (CI) and Poisson regression for the incidence rate ratio (IRR).
Results
1104 patients (73.3% female) with 1366 AA, predominantly mild (87.2%), were analyzed. The overall incidence of AEs was 251.75 per 1000 patient-years. Infections were the most frequent (55.0%), with an incidence of 138.4 per 1000 patient-years. Rheumatoid arthritis and corticosteroid use were associated with more global AEs, while anti-TNF was associated with less AEs.
Conclusions
This study from the BIOBADAGUAY registry has provided valuable data on the safety of DMARD-b, sd in a cohort of patients with inflammatory rheumatic diseases. The incidence of predominantly mild AEs, with infections as the most frequent adverse event, underscores the need for rigorous and constant monitoring in this population.
{"title":"Safety of biologic and synthetic targeted therapies in patients with immune-mediated diseases: data from the BIOBADAGUAY registry","authors":"Paloma de Abreu , Sonia Cabrera , Darwin Cordovilla , Lourdes Román , Cristina Brunengo , Patricia Melgarejo , Macarena Soto , Vannia Valinotti , Angelica Amarilla , Belem Acevedo , Alexis Pineda , Evelyn Leiva , Paola Pusineri , Sandra Consani , Mariela Zarza , Clyde Parodi , Zoilo Morel , Roger Rolón , Paola Jara , Raquel Aranda , Rosario Jurado","doi":"10.1016/j.reumae.2025.101798","DOIUrl":"10.1016/j.reumae.2025.101798","url":null,"abstract":"<div><h3>Objective</h3><div>To analyze the safety of biologic (DMARDs-b) and synthetic targeted therapies (DMARDs-sd) in the BIOBADAGUAY registry (Paraguayan-Uruguayan registry of adverse events (AEs) in patients with inflammatory rheumatic diseases).</div></div><div><h3>Methods</h3><div>BIOBADAGUAY is a registry to prospectively evaluate the efficacy and safety of FAME-b and FAME-sd. The full methodology is available at <span><span>https://biobadaguay.ser.es</span><svg><path></path></svg></span>. Variables associated with the safety of the therapies were used for the present study. The incidence of AA was calculated as incidence rate (IR) per 1000 patient-years, with 95% confidence intervals (CI) and Poisson regression for the incidence rate ratio (IRR).</div></div><div><h3>Results</h3><div>1104 patients (73.3% female) with 1366 AA, predominantly mild (87.2%), were analyzed. The overall incidence of AEs was 251.75 per 1000 patient-years. Infections were the most frequent (55.0%), with an incidence of 138.4 per 1000 patient-years. Rheumatoid arthritis and corticosteroid use were associated with more global AEs, while anti-TNF was associated with less AEs.</div></div><div><h3>Conclusions</h3><div>This study from the BIOBADAGUAY registry has provided valuable data on the safety of DMARD-b, sd in a cohort of patients with inflammatory rheumatic diseases. The incidence of predominantly mild AEs, with infections as the most frequent adverse event, underscores the need for rigorous and constant monitoring in this population.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 2","pages":"Article 101798"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143506632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.reumae.2025.501812
Juan Sebastián Almánzar Cortés , Cathalina Vergara Cabra , María Paula Uchima-Vera , Gerardo Quintana , Fernando Sierra
Introduction
Autoimmune hepatitis (AIH) is a chronic inflammatory liver disease with low prevalence worldwide. The coexistence of this entity with rheumatic diseases has been evaluated in multiple studies and is highly variable. The objective of this study is to identify the frequency of coexistence of rheumatic diseases and autoimmune hepatitis in adults who have been treated for 10 years in a fourth-level hospital in Bogota, Colombia.
Materials and methods
Analytical, observational, cross-sectional study in a single center that included patients over 18 years of age of both sexes with a diagnosis of AIH by simplified score ≥7 points, with a medical history registered at the Fundacion Santa Fe de Bogota in Bogota, Colombia between January 2013 and December 2023.
Results
A total of 66 patients met inclusion criteria. 36.4% of patients had a concomitant autoimmune disease, with Sjögren's syndrome, systemic lupus erythematosus and autoimmune thyroid disease being the most prevalent.
Conclusion
The frequency of coexistence of autoimmune hepatitis with rheumatic diseases in adult patients is 36.4% for the cohort studied, which is within the range of what has already been reported globally, where a prevalence of 14 to 44% has been described.
{"title":"Rheumatological diseases in patients with autoimmune hepatitis in a fourth level hospital in Bogotá between 2013 and 2023","authors":"Juan Sebastián Almánzar Cortés , Cathalina Vergara Cabra , María Paula Uchima-Vera , Gerardo Quintana , Fernando Sierra","doi":"10.1016/j.reumae.2025.501812","DOIUrl":"10.1016/j.reumae.2025.501812","url":null,"abstract":"<div><h3>Introduction</h3><div>Autoimmune hepatitis (AIH) is a chronic inflammatory liver disease with low prevalence worldwide. The coexistence of this entity with rheumatic diseases has been evaluated in multiple studies and is highly variable. The objective of this study is to identify the frequency of coexistence of rheumatic diseases and autoimmune hepatitis in adults who have been treated for 10 years in a fourth-level hospital in Bogota, Colombia.</div></div><div><h3>Materials and methods</h3><div>Analytical, observational, cross-sectional study in a single center that included patients over 18 years of age of both sexes with a diagnosis of AIH by simplified score ≥7 points, with a medical history registered at the Fundacion Santa Fe de Bogota in Bogota, Colombia between January 2013 and December 2023.</div></div><div><h3>Results</h3><div>A total of 66 patients met inclusion criteria. 36.4% of patients had a concomitant autoimmune disease, with Sjögren's syndrome, systemic lupus erythematosus and autoimmune thyroid disease being the most prevalent.</div></div><div><h3>Conclusion</h3><div>The frequency of coexistence of autoimmune hepatitis with rheumatic diseases in adult patients is 36.4% for the cohort studied, which is within the range of what has already been reported globally, where a prevalence of 14 to 44% has been described.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 2","pages":"Article 501812"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143506625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.reumae.2025.101802
Juan Pablo Ford , Enrique Roberto Soriano , Mauro Andreu
Background and objective
Juvenile idiopathic arthritis (JIA) has a generalized impact on physical function, thus functional capacity (FC) is one of the main outcome measures in this population. FC can be evaluated using self-referential questionnaires and with observational tests such as the Functional Ability Scale (CAPFUN). The psychometric properties of this scale have not been tested yet.
The objective of this study to evaluate the psychometric properties of the CAPFUN in children with JIA according to Consensus-based Standards for the selection of health Measurements Instruments (COSMIN).
Material and methods
Psychometric properties measurement study. Children were admitted between January 2018 and November 2019. Inclusion criteria: age between 6 and 16 years, diagnosis of JIA, complete physical therapy evaluation, including: CAPFUN scale, Childhood Health Assessment Questionnaire (C-HAQ), Visual Numerical Scale of patient's self-perceived Functional Capacity (VNSFC), Global Rating of Change (GROC) scale and Steinbrocker Scale. Subjects who discontinued follow-up were excluded. The psychometric properties evaluated were: reliability, construct validity, responsiveness, and interpretability.
Results
A total of 114 children were analyzed. The internal consistency was acceptable, as indicated by a Cronbach alpha of 0.93. Test–retest reliability showed a high level of consistency with an intraclass correlation coefficient of 0.999 (95% CI: 0.998–0.999). Regarding structural validity, the exploratory factor analysis yielded acceptable results, demonstrating the reliability of the instrument. All correlation coefficients were strong and all predetermined hypotheses were verified. The minimal clinically important difference was 0.04. [AUC 0.90 (95% CI: 0.83–0.91)].
Conclusions
The evaluations of the psychometric properties of the CAPFUN were satisfactory, demonstrating acceptable values for reliability, construct validity, responsiveness, and interpretability. Based on these results, this tool can effectively assess FC in children with JIA, both in clinical practice and research contexts.
{"title":"Evaluation of the psychometric properties of the Functional Ability Scale in children with juvenile idiopathic arthritis","authors":"Juan Pablo Ford , Enrique Roberto Soriano , Mauro Andreu","doi":"10.1016/j.reumae.2025.101802","DOIUrl":"10.1016/j.reumae.2025.101802","url":null,"abstract":"<div><h3>Background and objective</h3><div>Juvenile idiopathic arthritis (JIA) has a generalized impact on physical function, thus functional capacity (FC) is one of the main outcome measures in this population. FC can be evaluated using self-referential questionnaires and with observational tests such as the Functional Ability Scale (CAPFUN). The psychometric properties of this scale have not been tested yet.</div><div>The objective of this study to evaluate the psychometric properties of the CAPFUN in children with JIA according to Consensus-based Standards for the selection of health Measurements Instruments (COSMIN).</div></div><div><h3>Material and methods</h3><div>Psychometric properties measurement study. Children were admitted between January 2018 and November 2019. Inclusion criteria: age between 6 and 16 years, diagnosis of JIA, complete physical therapy evaluation, including: CAPFUN scale, Childhood Health Assessment Questionnaire (C-HAQ), Visual Numerical Scale of patient's self-perceived Functional Capacity (VNSFC), Global Rating of Change (GROC) scale and Steinbrocker Scale. Subjects who discontinued follow-up were excluded. The psychometric properties evaluated were: reliability, construct validity, responsiveness, and interpretability.</div></div><div><h3>Results</h3><div>A total of 114 children were analyzed. The internal consistency was acceptable, as indicated by a Cronbach alpha of 0.93. Test–retest reliability showed a high level of consistency with an intraclass correlation coefficient of 0.999 (95% CI: 0.998–0.999). Regarding structural validity, the exploratory factor analysis yielded acceptable results, demonstrating the reliability of the instrument. All correlation coefficients were strong and all predetermined hypotheses were verified. The minimal clinically important difference was 0.04. [AUC 0.90 (95% CI: 0.83–0.91)].</div></div><div><h3>Conclusions</h3><div>The evaluations of the psychometric properties of the CAPFUN were satisfactory, demonstrating acceptable values for reliability, construct validity, responsiveness, and interpretability. Based on these results, this tool can effectively assess FC in children with JIA, both in clinical practice and research contexts.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 2","pages":"Article 101802"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143578538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.reumae.2025.501814
Emine Uslu , Müçteba Enes Yayla , Didem Şahin-Eroğlu , Büşra Atmaca-Haktaniyan , Nilgün Göveç-Giynaş , Recep Yilmaz , Ahmet İlbay , Abdulbaki Gaydan , Yeter Mahmutoğlu , Ahmet Usta , Tahsin Murat Turgaya , Gülay Kinikli , Aşkın Ateş
Backgrounds
Adult-onset Still's Disease (AOSD) is a systemic inflammatory disorder. There is no definitive AOSD activity indicator. Two of the currently used disease activity scores are the Modified Pouchot Activity Score (mPoS), and Systemic Feature Score (SFS). Another scoring system has been recently introduced, named the Still Activity Score (SAS).
Aims
In this single-center cross-sectional study, we aimed to compare the performance of the SAS with the mPoS and SFS, both of which have been used for a long time for measuring disease activity in patients with AOSD.
Method
69 patients aged 18 or older were screened in the study who attended the Ankara University Faculty of Medicine between 2010 and 2020 with a diagnosis of AOSD. We compared SAS, SFS and mPoS with physician global assessment (PhGA) in patients with AOSD.
Results
Of 69 patients screened, 45 patients with AOSD who fulfilled the Yamaguchi criteria were analyzed. The results showed no significant difference in SAS between patients with PhGA < 6 and PhGA ≥ 6, but mPoS and SFS scores were higher in the PhGA ≥ 6 group (p = 0.053, p = 0.001, p = 0.007, respectively). There was a significant correlation between mPoS and PhGA (p = 0.018).
Conclusion
This is the first study to evaluate the SAS score, which is used for patients with AOSD. SAS is user-friendly but may not be as sensitive as mPoS and SFS for assessing disease activity in AOSD.
{"title":"Evaluation of performance of the Still Activity Score for assessment of Adult-onset Still's Disease: Comparative study with Systemic Feature Score and Modified Pouchot-Activity Score","authors":"Emine Uslu , Müçteba Enes Yayla , Didem Şahin-Eroğlu , Büşra Atmaca-Haktaniyan , Nilgün Göveç-Giynaş , Recep Yilmaz , Ahmet İlbay , Abdulbaki Gaydan , Yeter Mahmutoğlu , Ahmet Usta , Tahsin Murat Turgaya , Gülay Kinikli , Aşkın Ateş","doi":"10.1016/j.reumae.2025.501814","DOIUrl":"10.1016/j.reumae.2025.501814","url":null,"abstract":"<div><h3>Backgrounds</h3><div>Adult-onset Still's Disease (AOSD) is a systemic inflammatory disorder. There is no definitive AOSD activity indicator. Two of the currently used disease activity scores are the Modified Pouchot Activity Score (mPoS), and Systemic Feature Score (SFS). Another scoring system has been recently introduced, named the Still Activity Score (SAS).</div></div><div><h3>Aims</h3><div>In this single-center cross-sectional study, we aimed to compare the performance of the SAS with the mPoS and SFS, both of which have been used for a long time for measuring disease activity in patients with AOSD.</div></div><div><h3>Method</h3><div>69 patients aged 18 or older were screened in the study who attended the Ankara University Faculty of Medicine between 2010 and 2020 with a diagnosis of AOSD. We compared SAS, SFS and mPoS with physician global assessment (PhGA) in patients with AOSD.</div></div><div><h3>Results</h3><div>Of 69 patients screened, 45 patients with AOSD who fulfilled the Yamaguchi criteria were analyzed. The results showed no significant difference in SAS between patients with PhGA<!--> <!--><<!--> <!-->6 and PhGA<!--> <!-->≥<!--> <!-->6, but mPoS and SFS scores were higher in the PhGA<!--> <!-->≥<!--> <!-->6 group (<em>p</em> <!-->=<!--> <!-->0.053, <em>p</em> <!-->=<!--> <!-->0.001, <em>p</em> <!-->=<!--> <!-->0.007, respectively). There was a significant correlation between mPoS and PhGA (<em>p</em> <!-->=<!--> <!-->0.018).</div></div><div><h3>Conclusion</h3><div>This is the first study to evaluate the SAS score, which is used for patients with AOSD. SAS is user-friendly but may not be as sensitive as mPoS and SFS for assessing disease activity in AOSD.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 2","pages":"Article 501814"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143578522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Intestinal perforation, a rare complication of interleukin (IL)-6 therapy for immune-mediated diseases (mainly rheumatoid arthritis), typically manifests in the lower gastrointestinal tract, often in association with prior history of diverticulitis. Patients may present with acute abdominal pain and suspicion for this complication should remain high even in the absence of elevated C-reactive protein. We describe a 69-year-old female patient with a history of resistant seropositive palindromic rheumatism treated with sarilumab who developed a nontraumatic terminal ileal perforation.
{"title":"Nontraumatic terminal ileal perforation in a patient with resistant palindromic rheumatism treated with sarilumab: A case report","authors":"Anastasia Mocritcaia , Rocío García-Pérez , Beatriz Frade , Raimon Sanmartí","doi":"10.1016/j.reumae.2025.501811","DOIUrl":"10.1016/j.reumae.2025.501811","url":null,"abstract":"<div><div>Intestinal perforation, a rare complication of interleukin (IL)-6 therapy for immune-mediated diseases (mainly rheumatoid arthritis), typically manifests in the lower gastrointestinal tract, often in association with prior history of diverticulitis. Patients may present with acute abdominal pain and suspicion for this complication should remain high even in the absence of elevated C-reactive protein. We describe a 69-year-old female patient with a history of resistant seropositive palindromic rheumatism treated with sarilumab who developed a nontraumatic terminal ileal perforation.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 2","pages":"Article 501811"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143538286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.reumae.2025.501813
Rosa I. Arvizu-Rivera , Jesus A. Cardenas-de la Garza , Valeria Gonzalez-Gonzalez , Dionicio A. Galarza-Delgado , Jose R. Azpiri-Lopez , Andrea L. Guajardo-Aldaco , Maria F. Elizondo-Benitez , Iris J. Colunga-Pedraza
Objective
The aim of this study was to determine the prevalence of cardiovascular risk factors and comorbidities in a cohort of Mexican Mestizo rheumatoid arthritis (RA) patients.
Methods
We performed an observational and cross-sectional study involving the RA cohort of our Cardio-Rheumatology Clinic in a teaching hospital. The cohort includes patients aged 40–75 years old who fulfilled the ACR/EULAR classification criteria for RA, patients were recruited from August 2014 to July 2023. Cardiovascular risk factors and comorbidities were defined as a diagnosis included in the patient's medical record or the use of treatment for these conditions.
Results
523 patients with RA were included; the majority were women (92.3%). The median age was 55 (48.9–61.0) years. The most prevalent cardiovascular risk factors were overweight (219, 42%), obesity (157, 32.0%), dyslipidemia (165, 31.5%), and hypertension (164, 31.3%). We also detected, that 12.1% of patients without a diagnosis of hypertension had elevated blood pressure, hyperglycemia was reported in 17.2%, and lipid profile alterations were present in 70.6% of patients with no previous diagnosis of type 2 diabetes mellitus and dyslipidemia, respectively.
Conclusion
Cardiovascular risk factors are prevalent in patients with rheumatoid arthritis. Overweight, obesity, and dyslipidemia were the most prevalent cardiovascular risk factors in our cohort. Alterations in the lipid profile were reported in half of the patients with no previous diagnosis of dyslipidemia.
{"title":"Comorbidities in Mexican Mestizo patients with rheumatoid arthritis: A cross-sectional study of 523 patients in a preventive cardio-rheumatology clinic","authors":"Rosa I. Arvizu-Rivera , Jesus A. Cardenas-de la Garza , Valeria Gonzalez-Gonzalez , Dionicio A. Galarza-Delgado , Jose R. Azpiri-Lopez , Andrea L. Guajardo-Aldaco , Maria F. Elizondo-Benitez , Iris J. Colunga-Pedraza","doi":"10.1016/j.reumae.2025.501813","DOIUrl":"10.1016/j.reumae.2025.501813","url":null,"abstract":"<div><h3>Objective</h3><div>The aim of this study was to determine the prevalence of cardiovascular risk factors and comorbidities in a cohort of Mexican Mestizo rheumatoid arthritis (RA) patients.</div></div><div><h3>Methods</h3><div>We performed an observational and cross-sectional study involving the RA cohort of our Cardio-Rheumatology Clinic in a teaching hospital. The cohort includes patients aged 40–75 years old who fulfilled the ACR/EULAR classification criteria for RA, patients were recruited from August 2014 to July 2023. Cardiovascular risk factors and comorbidities were defined as a diagnosis included in the patient's medical record or the use of treatment for these conditions.</div></div><div><h3>Results</h3><div>523 patients with RA were included; the majority were women (92.3%). The median age was 55 (48.9–61.0) years. The most prevalent cardiovascular risk factors were overweight (219, 42%), obesity (157, 32.0%), dyslipidemia (165, 31.5%), and hypertension (164, 31.3%). We also detected, that 12.1% of patients without a diagnosis of hypertension had elevated blood pressure, hyperglycemia was reported in 17.2%, and lipid profile alterations were present in 70.6% of patients with no previous diagnosis of type 2 diabetes mellitus and dyslipidemia, respectively.</div></div><div><h3>Conclusion</h3><div>Cardiovascular risk factors are prevalent in patients with rheumatoid arthritis. Overweight, obesity, and dyslipidemia were the most prevalent cardiovascular risk factors in our cohort. Alterations in the lipid profile were reported in half of the patients with no previous diagnosis of dyslipidemia.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 2","pages":"Article 501813"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143578521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.reumae.2025.501808
Laura Farran Ortega , Rosa Fornons-Servent , Joan Miquel Nolla , Xavier Juanola Roura
Objectives
To determine the prevalence of hidradenitis suppurativa (HS) in patients with axial spondyloarthritis (AxSpA) and to describe clinical, laboratory, and radiographic characteristics of patients diagnosed with HS.
Patients and methods
We performed a cross-sectional study of a cohort of 265 patients with AxSpA in follow-up at a tertiary hospital. Patients were screened for HS using a questionnaire, with subsequent diagnostic confirmation by a dermatologist. We collected demographic, clinical, laboratory, and radiographic data. Patients were classified by diagnosis of HS. A descriptive analysis and comparison were performed for both groups.
Results
A total of 148 of the 265 patients (55.8%) completed the screening questionnaire. Screening was positive in 9 patients (6.1%), although the diagnosis of HS was confirmed in only 4 (2.7%). Three patients were diagnosed during the study, with a mean diagnostic delay of 14.25 years. All the patients had mild HS (Hurley stage I). When patients with and without HS were compared, the HS group had more smokers (75% vs 18%; p = 0.005), greater disease activity according to BASDAI (5.6 ± 2.3 vs 3.2 ± 2.1; p = 0.026), less structural damage according to the axial BASRI (1.5 ± 1.3 vs 5.5 ± 3.5; p < 0.018) and shorter time since diagnosis of AxSpA (14.7 ± 2.6 vs 27.8 ± 13.5 years; p = 0.001). No significant differences were found for the remaining variables studied.
Conclusion
This study suggests that prevalence of HS in patients with axSpA is higher than the one observed in general population. The knowledge of this association should encourage clinicians to inquire about symptoms of HS and actively search for lesions.
{"title":"Prevalence of hidradenitis suppurativa in patients with axial spondyloarthritis","authors":"Laura Farran Ortega , Rosa Fornons-Servent , Joan Miquel Nolla , Xavier Juanola Roura","doi":"10.1016/j.reumae.2025.501808","DOIUrl":"10.1016/j.reumae.2025.501808","url":null,"abstract":"<div><h3>Objectives</h3><div>To determine the prevalence of hidradenitis suppurativa (HS) in patients with axial spondyloarthritis (AxSpA) and to describe clinical, laboratory, and radiographic characteristics of patients diagnosed with HS.</div></div><div><h3>Patients and methods</h3><div>We performed a cross-sectional study of a cohort of 265 patients with AxSpA in follow-up at a tertiary hospital. Patients were screened for HS using a questionnaire, with subsequent diagnostic confirmation by a dermatologist. We collected demographic, clinical, laboratory, and radiographic data. Patients were classified by diagnosis of HS. A descriptive analysis and comparison were performed for both groups.</div></div><div><h3>Results</h3><div>A total of 148 of the 265 patients (55.8%) completed the screening questionnaire. Screening was positive in 9 patients (6.1%), although the diagnosis of HS was confirmed in only 4 (2.7%). Three patients were diagnosed during the study, with a mean diagnostic delay of 14.25 years. All the patients had mild HS (Hurley stage I). When patients with and without HS were compared, the HS group had more smokers (75% vs 18%; p = 0.005), greater disease activity according to BASDAI (5.6 ± 2.3 vs 3.2 ± 2.1; p = 0.026), less structural damage according to the axial BASRI (1.5 ± 1.3 vs 5.5 ± 3.5; p < 0.018) and shorter time since diagnosis of AxSpA (14.7 ± 2.6 vs 27.8 ± 13.5 years; p = 0.001). No significant differences were found for the remaining variables studied.</div></div><div><h3>Conclusion</h3><div>This study suggests that prevalence of HS in patients with axSpA is higher than the one observed in general population. The knowledge of this association should encourage clinicians to inquire about symptoms of HS and actively search for lesions.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 2","pages":"Article 501808"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143506581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Examining cytokine profile complexities in chronic autoimmune disorders holds significant clinical importance. In order to address the similarities and differences related to SLE and RA, it was necessary to evaluate their cytokine chemokine profiles. Such analyses would give pointers towards differences, leading thereby to explore the potential of cytokines/chemokines as biomarkers. The study was therefore driven by the concept of understanding the major differences at this level with a hope of contribution towards diagnostics/theranostics. A multiplex study was carried out on systemic autoimmune disorders, such as SLE and RA, analysing forty analytes in comparison with healthy controls.
Methodology
Age and sex matched healthy donors and patients (n = 38) were recruited and plasma cytokine profiling was done by Bio-plex multiplex immunoassay system.
Results
A comparison with healthy volunteers revealed differential alteration in various chemokines in SLE and RA, respectively. Protein interaction analysis identified a core complex of chemokines (CXCL10, CCL5, CXCL12, CXCL9, CXCL1, and CXCL27) as central modulators, suggesting their potential as biomarkers. Drug prediction using the DSigDB database identified acetovanillone as a potential drug against this core complex. In comparing lupus patients with or without arthritis comorbidity, elevated levels of cytokines: IL-12, SCF, and TNF-a were prominently associated with arthritis in SLE. TNF-a emerged as a potential indicator specifically for arthritis.
Conclusion
This study enhances our understanding of the complex interplay of cytokine/chemokine in these systemic conditions and suggests their utility as targets and diagnostic paradigms for detection.
{"title":"Investigating potential biomarkers and therapeutic targets for patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) through the utilization of cytokine profiling","authors":"Akhil Akhil , Rohit Bansal , Jyotsana Kaushal , Aman Sharma , Archana Bhatnagar","doi":"10.1016/j.reumae.2025.101805","DOIUrl":"10.1016/j.reumae.2025.101805","url":null,"abstract":"<div><h3>Objectives</h3><div>Examining cytokine profile complexities in chronic autoimmune disorders holds significant clinical importance. In order to address the similarities and differences related to SLE and RA, it was necessary to evaluate their cytokine chemokine profiles. Such analyses would give pointers towards differences, leading thereby to explore the potential of cytokines/chemokines as biomarkers. The study was therefore driven by the concept of understanding the major differences at this level with a hope of contribution towards diagnostics/theranostics. A multiplex study was carried out on systemic autoimmune disorders, such as SLE and RA, analysing forty analytes in comparison with healthy controls.</div></div><div><h3>Methodology</h3><div>Age and sex matched healthy donors and patients (<em>n</em> <!-->=<!--> <!-->38) were recruited and plasma cytokine profiling was done by Bio-plex multiplex immunoassay system.</div></div><div><h3>Results</h3><div>A comparison with healthy volunteers revealed differential alteration in various chemokines in SLE and RA, respectively. Protein interaction analysis identified a core complex of chemokines (CXCL10, CCL5, CXCL12, CXCL9, CXCL1, and CXCL27) as central modulators, suggesting their potential as biomarkers. Drug prediction using the DSigDB database identified acetovanillone as a potential drug against this core complex. In comparing lupus patients with or without arthritis comorbidity, elevated levels of cytokines: IL-12, SCF, and TNF-a were prominently associated with arthritis in SLE. TNF-a emerged as a potential indicator specifically for arthritis.</div></div><div><h3>Conclusion</h3><div>This study enhances our understanding of the complex interplay of cytokine/chemokine in these systemic conditions and suggests their utility as targets and diagnostic paradigms for detection.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 1","pages":"Article 101805"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143082799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.reumae.2025.101803
Hend Adel , Ahmed A. Eldeeb , Fatma Hamdy
Introduction and objectives
Glomerulonephritis is a heterogenous group of diseases which is diagnosed mainly by renal biopsy. This study aims to assess nailfold capillaroscopic changes in patients with glomerular diseases.
Patients and methods
This study was conducted on 50 patients with glomerular disease confirmed by renal biopsy and 50 age and sex matched healthy controls. Clinical, laboratory evaluation and nailfold capillaroscopic examination were done for all participants.
Results
Lupus nephritis was the most common pathological type among glomerulonephritis group [17 (34%)], followed by focal segmental glomerulosclerosis [9 (18%)]. Tortuous capillaries were significantly higher in patients with primary glomerular diseases compared to healthy persons (92.9% vs 58%, P < 0.001). The diameter was significantly lower in patients with primary glomerular diseases compared to healthy control group (15.6 μm vs 18.9 μm, P = 0.001). Subpapillary venous plexus (28.6% vs 6%, P = 0.02) and capillary microhemorrhage (32% vs 0%, P < 0.001) were significantly more frequent in patients with primary glomerular diseases compared to the control group. Patients with lupus nephritis had higher capillary diameter (19.5 vs 15.6 μm, P = 0.02), width (55.6 vs 44 μm, P = 0.003) and microhemorrhage (64.7% vs 32%, P = 0.03) compared to patients with primary glomerulonephritis. There was a statistically significant difference as regard diameter (P = 0.005) and length (P = 0.02) between different classes of lupus nephritis.
Conclusion
More tortious capillaries and lower capillary diameter were found in patients with primary glomerular disease compared to healthy persons. Lupus nephritis patients had more dilated capillaries and more capillary microhemorrhage compared to primary glomerulonephritis patients.
{"title":"Nailfold capillaroscopic changes in patients with glomerular diseases","authors":"Hend Adel , Ahmed A. Eldeeb , Fatma Hamdy","doi":"10.1016/j.reumae.2025.101803","DOIUrl":"10.1016/j.reumae.2025.101803","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>Glomerulonephritis is a heterogenous group of diseases which is diagnosed mainly by renal biopsy. This study aims to assess nailfold capillaroscopic changes in patients with glomerular diseases.</div></div><div><h3>Patients and methods</h3><div>This study was conducted on 50 patients with glomerular disease confirmed by renal biopsy and 50 age and sex matched healthy controls. Clinical, laboratory evaluation and nailfold capillaroscopic examination were done for all participants.</div></div><div><h3>Results</h3><div>Lupus nephritis was the most common pathological type among glomerulonephritis group [17 (34%)], followed by focal segmental glomerulosclerosis [9 (18%)]. Tortuous capillaries were significantly higher in patients with primary glomerular diseases compared to healthy persons (92.9% vs 58%, <em>P</em> <!--><<!--> <!-->0.001). The diameter was significantly lower in patients with primary glomerular diseases compared to healthy control group (15.6<!--> <!-->μm vs 18.9<!--> <!-->μm, <em>P</em> <!-->=<!--> <!-->0.001). Subpapillary venous plexus (28.6% vs 6%, <em>P</em> <!-->=<!--> <!-->0.02) and capillary microhemorrhage (32% vs 0%, <em>P</em> <!--><<!--> <!-->0.001) were significantly more frequent in patients with primary glomerular diseases compared to the control group. Patients with lupus nephritis had higher capillary diameter (19.5 vs 15.6<!--> <!-->μm, <em>P</em> <!-->=<!--> <!-->0.02), width (55.6 vs 44<!--> <!-->μm, <em>P</em> <!-->=<!--> <!-->0.003) and microhemorrhage (64.7% vs 32%, <em>P</em> <!-->=<!--> <!-->0.03) compared to patients with primary glomerulonephritis. There was a statistically significant difference as regard diameter (<em>P</em> <!-->=<!--> <!-->0.005) and length (<em>P</em> <!-->=<!--> <!-->0.02) between different classes of lupus nephritis.</div></div><div><h3>Conclusion</h3><div>More tortious capillaries and lower capillary diameter were found in patients with primary glomerular disease compared to healthy persons. Lupus nephritis patients had more dilated capillaries and more capillary microhemorrhage compared to primary glomerulonephritis patients.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 1","pages":"Article 101803"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143082835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.reumae.2025.501810
Marta de la Rubia Navarro, Samuel Leal Rodríguez, José Andrés Román Ivorra
Objective
The aim is to describe clinical and serological features, previous and current therapies, and adverse events in four systemic sclerosis patients (SSc) who undergo autologous hematopoietic stem cells transplantation (AHSCT).
Methods
Descriptive, cross-sectional study including SSc patients according ACR/EULAR 2013 criteria. Clinical and serological data, data related to current and previous therapy and adverse events were collected from 2014 to 2023.
Results
Four female patients were included, with a mean age of 49 (6.78) years old and a mean of 32.5 (7) months since diagnosis to AHSCT. Mean mRodnan score (mRSS) was 33.75. All cases underwent a skin improvement measured by mRSS (mean difference of 14.75) and lung function (DLCO) remained stable. Only one patient presented a pneumonia post-AHSCT, that required admission to intensive care unit, with improvement and complete resolution of infection a few days after admission.
Conclusions
AHSCT is an appropriate therapeutic option in rapidly progressive diffuse SSc patients, with a good safety profile in our cohort.
{"title":"Autologous stem cell transplantation in systemic sclerosis: 4 cases","authors":"Marta de la Rubia Navarro, Samuel Leal Rodríguez, José Andrés Román Ivorra","doi":"10.1016/j.reumae.2025.501810","DOIUrl":"10.1016/j.reumae.2025.501810","url":null,"abstract":"<div><h3>Objective</h3><div>The aim is to describe clinical and serological features, previous and current therapies, and adverse events in four systemic sclerosis patients (SSc) who undergo autologous hematopoietic stem cells transplantation (AHSCT).</div></div><div><h3>Methods</h3><div>Descriptive, cross-sectional study including SSc patients according ACR/EULAR 2013 criteria. Clinical and serological data, data related to current and previous therapy and adverse events were collected from 2014 to 2023.</div></div><div><h3>Results</h3><div>Four female patients were included, with a mean age of 49 (6.78) years old and a mean of 32.5 (7) months since diagnosis to AHSCT. Mean mRodnan score (mRSS) was 33.75. All cases underwent a skin improvement measured by mRSS (mean difference of 14.75) and lung function (DLCO) remained stable. Only one patient presented a pneumonia post-AHSCT, that required admission to intensive care unit, with improvement and complete resolution of infection a few days after admission.</div></div><div><h3>Conclusions</h3><div>AHSCT is an appropriate therapeutic option in rapidly progressive diffuse SSc patients, with a good safety profile in our cohort.</div></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"21 1","pages":"Article 501810"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143043985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号